Genelux Novel Imaging Technologies

cover image

A circulating tumor cell (center of photo) from a mouse bearing human prostate cancer detected by our Genelux virus (Blue=nuclei, Green=EpCam, Purple=Virus+Nucleus).

GL-ONC1 and other Genelux vaccinia-based vectors show great promise in the treatment of cancer. The company has also pioneered the development of non-invasive companion imaging capabilities for monitoring the therapeutic efficacy of its viral vectors, and which may aid in the diagnosis and staging of cancer and intra-operative scenarios.

Our leading product candidate, GL-ONC1, incorporates a unique luminescent fluorescent fusion protein, Renilla luciferase- Aequorea Green Fluorescent Protein (GFP) to enable companion optical imaging, This protein is a combination of two proteins from glowing sea pansies and jellyfish.

After the virus finds and enters a tumor, it begins to replicate, proportionally emitting light throughout the viral amplification process. In preclinical testing, this has enabled accurate, non-invasive detection and optical imaging of cancer progression/ regression in real time, as well as microscopic imaging of tumor biopsies at tissue or cellular levels.

Clinical trials of our flagship product GL-ONC1 will utilize this technology to supplement safety and efficacy evaluations. In the future, Genelux therapeutics may contain novel deep tissue imaging capabilities enabling use of PET and MRI scans.”